Cover Image
市場調查報告書

類升糖素肽2受體 (GLP-2受體,GLP2R):開發中產品分析

Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361651
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
類升糖素肽2受體 (GLP-2受體,GLP2R):開發中產品分析 Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 49 Pages
簡介

本報告提供全球各國的類升糖素肽2受體 (別名GLP-2受體或GLP2R)的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

  • 簡介
    • 分析範圍
  • 類升糖素肽2受體 (GLP-2受體,GLP2R)的概要
  • 治療藥的開發情形
    • 臨床實驗的各階段
    • 各治療領域
    • 各症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的治療藥
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥法
    • 各分子類型
  • 開發治療藥的企業
    • Naia Limited
    • Shire Plc
    • Tasly Pharmaceutical Group Co., Ltd.
    • Zealand Pharma A/S
  • 藥物簡介
    • FE-203799
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的發展情形
    • GXG-8
    • NB-1002
    • teduglutide (基因改造型)
    • ZP-1848
    • ZPGG-23
    • ZPGG-72
  • 開發暫停的產品
  • 值得注意的最新趨勢、新聞稿 (共15件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0087TDB

Summary

Global Markets Direct's, 'Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Review, H1 2016', provides in depth analysis on Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
  • The report reviews Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) Overview
    • Therapeutics Development
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Stage of Development
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Therapy Area
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Indication
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Products under Development by Companies
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Companies Involved in Therapeutics Development
    • Naia Limited
    • Shire Plc
    • Tasly Pharmaceutical Group Co., Ltd.
    • Zealand Pharma A/S
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Drug Profiles
    • FE-203799 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXG-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teduglutide (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-1848 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPGG-23 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPGG-72 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Dormant Projects
    • Glucagon-Like Peptide 2 Receptor (GLP-2 Receptor or GLP2R) - Featured News & Press Releases
      • Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
      • Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
      • Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
      • Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
      • Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
      • Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association's (ADA) 74th Scientific Sessions
      • Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
      • Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection
      • Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome
      • Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting
      • Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome
      • Jan 02, 2013: ThriveRx Receives Limited Distribution Rights To NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome In Adults
      • Dec 27, 2012: Coram Specialty Infusion Services To Provide NPS Pharma's Gattex For Treatment Of Short Bowel Syndrome
      • Dec 21, 2012: NPS Pharma's Gattex Receives FDA Approval For Treatment Of Short Bowel Syndrome
      • Nov 29, 2012: NPS Pharma Announces Publication Of Pivotal Phase III Study Of Gattex In Short Bowel Syndrome-intestinal Failure Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Naia Limited, H1 2016
  • Pipeline by Shire Plc, H1 2016
  • Pipeline by Tasly Pharmaceutical Group Co., Ltd., H1 2016
  • Pipeline by Zealand Pharma A/S, H1 2016
  • Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top